Prognostic Model of Hypertension
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Standard therapy.
- Who it may be relevant to
- Registry conditions: Hypertension. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.
Detailed description
The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.
Interventions
- Other Standard therapy
Individualized blood pressure reduction program
Primary outcome measures
- Resistant hypertension [Time frame: 10 years of follow-up Resistant hypertension occurred during this period]
- Death (all-cause mortality, mortality from hypertension complications) [Time frame: 10 years of follow-up deaths occurred during this period]
Secondary outcome measures (1)
- Major adverse cardiovascular events [Time frame: 10 years of follow-up deaths occurred during this period]
Eligibility criteria
Inclusion criteria
- A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Exclusion criteria
- Patients with secondary hypertension, patients with liver and kidney dysfunction,
- patients with mental disorders, and patients who are unwilling to participate in this trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The First Affiliated Hospital of Xinjiang Medicial University — Ürümqi
Identifiers
NCT: NCT06160921 · 20190818